Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $686.4 million.

  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities fell 18.83% to $686.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.4 million, marking a year-over-year decrease of 18.83%. This contributed to the annual value of $686.4 million for FY2025, which is 18.83% down from last year.
  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities amounted to $686.4 million in Q3 2025, which was up 3.02% from $666.3 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $863.9 million for Q4 2024, and its period low was $102.6 million during Q2 2021.
  • In the last 3 years, Arrowhead Pharmaceuticals' Total Non-Current Liabilities had a median value of $448.1 million in 2024 and averaged $547.1 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Total Non-Current Liabilities soared by 916.01% in 2021, and later declined by 21.94% in 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $128.9 million in 2021, then surged by 189.35% to $373.1 million in 2022, then rose by 4.22% to $388.8 million in 2023, then skyrocketed by 122.16% to $863.9 million in 2024, then decreased by 18.83% to $686.4 million in 2025.
  • Its last three reported values are $686.4 million in Q3 2025, $666.3 million for Q2 2025, and $668.7 million during Q1 2025.